Immunomic Therapeutics
PrivateLast Round
VC Round
Jan 14, 2021
Total Funding Raised
$15.53M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Immunomic Therapeutics operates in Healthcare & Life Sciences and is based in Rockville, Maryland. Its latest recorded funding round was a VC Round in January 2021.
Immunomic Therapeutics is a biotechnology company that develops nucleic acid-based vaccines and immunotherapies for oncology, infectious diseases, and allergies using its proprietary UNITE platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunomic Therapeutics Comparables
Compare Immunomic Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MimiVax Inc. | 81% | |
| Takis S.r.l. | 78% | |
| Elicio Therapeutics | 77% |
For institutional investors. Book with your work email.
Immunomic Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 14, 2021 | ||||
| Debt | Mar 15, 2017 | ||||
| Series A | Oct 28, 2014 | ||||
| Debt | Jul 17, 2013 | ||||
| Angel | Mar 5, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immunomic Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Life Sciences Greenhouse Investments | Debt |
| Keiretsu Forum | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 6, 3x the trailing average.
- Jan 14, 2021
$78M round led by HLB Co., Ltd.
For institutional investors. Book with your work email.
Immunomic Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immunomic Therapeutics's valuation, stock price, and market status.
Is Immunomic Therapeutics a public or private company?
Immunomic Therapeutics is a private company.
What is the current stock price of Immunomic Therapeutics?
Immunomic Therapeutics is a private company, so its shares have no public market price. Caplight tracks Immunomic Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immunomic Therapeutics worth (valuation)?
Valuation information for Immunomic Therapeutics is not publicly available.
Can I buy Immunomic Therapeutics stock?
Immunomic Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immunomic Therapeutics's last funding round?
Immunomic Therapeutics's most recent funding round was VC Round on January 14, 2021.
Who are the main investors in Immunomic Therapeutics?
Key investors in Immunomic Therapeutics include Life Sciences Greenhouse Investments.
Will Immunomic Therapeutics IPO soon?
No public IPO plans have been announced for Immunomic Therapeutics.
How can I track Immunomic Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Immunomic Therapeutics's shares on secondary markets.